Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Testosterone therapy--what, when and to whom?

F Jockenhövel1

  • 1Department of Medicine, Evangelisches Krankenhaus Herne, Wiescherstrasse 24, 44623 Herne, Germany.

The Aging Male : the Official Journal of the International Society for the Study of the Aging Male
|April 1, 2005
PubMed
Summary

Testosterone therapy effectively treats male hypogonadism, including age-related forms. Newer formulations like testosterone gel and long-acting injections offer improved efficacy and patient satisfaction compared to older methods.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Complete atrioventricular block during lithium therapy within therapeutic range].

Deutsche medizinische Wochenschrift (1946)·2012
Same author

[Testosterone and the metabolic syndrome].

Der Urologe. Ausg. A·2010
Same author

Comparison of long-acting testosterone undecanoate formulation versus testosterone enanthate on sexual function and mood in hypogonadal men.

European journal of endocrinology·2009
Same author

Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism.

Journal of endocrinological investigation·2008
Same author

A four-year efficacy and safety study of the long-acting parenteral testosterone undecanoate.

The aging male : the official journal of the International Society for the Study of the Aging Male·2007
Same author

[LOH (late-onset hypogonadism) or the "aging male"].

Der Urologe. Ausg. A·2006

Area of Science:

  • Endocrinology
  • Andrology
  • Pharmacology

Background:

  • Male hypogonadism, characterized by low testosterone, has classical and age-related forms.
  • Increasing age leads to decreased testosterone production in many men, affecting 15-25% over 50.
  • Testosterone therapy is indicated for hypogonadism when clinical symptoms are present.

Purpose of the Study:

  • To review current and emerging testosterone therapy options for male hypogonadism.
  • To compare the efficacy and patient satisfaction of different testosterone delivery systems.
  • To highlight new formulations suitable for elderly men and classical hypogonadism.

Main Methods:

  • Review of existing literature on testosterone therapy and hypogonadism.
  • Analysis of clinical outcomes and side-effect profiles of various testosterone formulations.

Related Experiment Videos

  • Evaluation of pharmacokinetic data for novel delivery systems.

    • Main Results:

    • Testosterone gel offers efficient delivery with fewer side effects and higher patient satisfaction than patches.
    • Intramuscular testosterone undecanoate provides stable serum testosterone levels with infrequent injections (every 3 months).
    • Both testosterone gel and intramuscular testosterone undecanoate show promise as preferred future therapies.

    Conclusions:

    • Newer testosterone formulations, including hydroalcoholic gel and long-acting intramuscular injections, represent significant advancements.
    • These novel methods offer improved efficacy, tolerability, and patient convenience for managing hypogonadism.
    • Testosterone gel is suitable for elderly men, while intramuscular testosterone undecanoate is ideal for long-term substitution in classical hypogonadism.